ANVS Share Price | Annovis Bio, Inc. Stock Analysis & Recommendation

Q: How big is Annovis Bio, Inc.?

Market Cap: As of Jun 18, Annovis Bio, Inc. has a market capitalization of 51.25 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Annovis Bio, Inc. reported net sales of 0.00 million and a net profit of -29.06 million.Balance Sheet Snapshot: As of Dec'24, the company's shareholder's funds amounted to 9.31 million, while total assets were reported at 13.93 million.

Q: What does Annovis Bio, Inc. do?

Overview: Annovis Bio, Inc. is a clinical stage, drug platform company focused on addressing neurodegeneration, such as Alzheimer's disease and Parkinson's disease, within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -6 Million (Quarterly Results - Mar 2025) Market cap: USD 51.25 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.92 Return on Equity: -110.36% Price to Book: 2.13Contact Details: Address: 1055 Westlakes Dr Ste 300, BERWYN PA: 19312-2410 Tel: 1 610 7273913 Fax: 1 610 7274001 Website: https://www.annovisbio.com/

Q: Is Annovis Bio, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Annovis Bio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a bearish daily moving average and a weekly MACD that is mildly bullish, indicating mixed signals. The Bollinger Bands are bearish on the weekly and mildly bearish on the monthly, while the KST shows a mildly bearish weekly trend and a bearish monthly trend. Additionally, there is no trend indicated by Dow Theory or OBV. In terms of performance, the stock has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -53.28% compared to the S&P 500's 12.22%.

Results Declared: Annovis Bio, Inc. has declared results on 13 Mar 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

741.05 k

Shareholding (Dec 2025)

FII

3.33%

Held by 14 FIIs

DII

92.66%

Held by 5 DIIs

Promoter

0.00%

How big is Annovis Bio, Inc.?

22-Jun-2025

As of Jun 18, Annovis Bio, Inc. has a market capitalization of 51.25 million, with net sales of 0.00 million and a net profit of -29.06 million over the latest four quarters. As of Dec'24, shareholder's funds were 9.31 million and total assets were 13.93 million.

View full answer

What does Annovis Bio, Inc. do?

22-Jun-2025

Annovis Bio, Inc. is a clinical stage pharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. As of March 2025, it has a market cap of $51.25 million and reported a net profit loss of $6 million.

View full answer

Who are in the management team of Annovis Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Annovis Bio, Inc. includes Chairman Mr. Michael Hoffman and Executive Board Member Dr. Maria Maccecchini, along with Board Members Dr. Claudine Bruck, Mr. Robert Whelan, and Mr. Mark White.

View full answer

Is Annovis Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Annovis Bio, Inc. shows a mildly bearish trend with mixed signals from technical indicators, significantly underperforming the S&P 500 with a year-to-date return of -53.28%.

View full answer

Compare Annovis Bio, Inc. with Similar Stocks

CytomX Therapeutics, Inc.aTyr Pharma, Inc.Chimerix, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 80 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.16

Return on Equity

-198.00%

Price to Book

6.10

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-29.16%

6 Months

10.64%

1 Year

46.07%

2 Years

-72.31%

3 Years

-83.24%

4 Years

-81.66%

5 Years

-92.78%

Annovis Bio, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-222.61%

EBIT to Interest (avg)

-22.48

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.92

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

18.92%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.10

EV to EBIT

-2.43

EV to EBITDA

-2.43

EV to Capital Employed

-30.49

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-198.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (4.01%)

Foreign Institutions

Held by 14 Foreign Institutions (3.33%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -66.10% vs 73.42% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.70",
          "val2": "-6.70",
          "chgp": "-44.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.30",
          "val2": "0.70",
          "chgp": "-142.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-9.80",
          "val2": "-5.90",
          "chgp": "-66.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -17.48% vs 56.23% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-29.70",
          "val2": "-26.70",
          "chgp": "-11.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "1.90",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "3.60",
          "chgp": "-97.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-28.90",
          "val2": "-24.60",
          "chgp": "-17.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.70

-6.70

-44.78%

Interest

0.00

Exceptional Items

-0.30

0.70

-142.86%

Consolidate Net Profit

-9.80

-5.90

-66.10%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -66.10% vs 73.42% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-29.70

-26.70

-11.24%

Interest

0.00

1.90

-100.00%

Exceptional Items

0.10

3.60

-97.22%

Consolidate Net Profit

-28.90

-24.60

-17.48%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -17.48% vs 56.23% in Dec 2024

All Annual Results

Company CV

About Annovis Bio, Inc.

Annovis Bio, Inc.

Pharmaceuticals & Biotechnology

Annovis Bio, Inc. is a clinical stage, drug platform company. The Company is focused on addressing neurodegeneration, such as Alzheimer's disease in Down syndrome (AD-DS), Alzheimer's disease (AD) and Parkinson's disease (PD). The Company is engaged in developing drugs that normalize the transport of information within and between nerve cells, called axonal transport. Its lead product pipelines are ANVS-401, which include ANVS-401 for AD, ANVS-401 for AD-DS, ANVS-401 for PD; ANVS-405 and ANVS-301. Its ANVS-401 restores axonal transport and homeostasis in the brain by inhibiting the synthesis of neurotoxic proteins. The Company is in an ongoing Phase II A proof-of-concept study in mild to moderate AD patients and a ready program to conduct a second Phase II A study in PD patients. The Company has also developed compound to treat acute neurodegeneration traumatic brain injury (TBI) and stroke.

Company Coordinates

Company Details

1055 Westlakes Dr Ste 300 , BERWYN PA : 19312-2410

Tel: 1 610 7273913

https://www.annovisbio.com/

Registrar Details